-+ 0.00%
-+ 0.00%
-+ 0.00%

Galderma's Relfydess improves frown lines, crow's feet in pooled Phase III data

PUBT·10/21/2026 05:01:37
Listen to the news
Galderma's Relfydess improves frown lines, crow's feet in pooled Phase III data
  • Galderma will present eight scientific abstracts on injectable aesthetic treatments at AMWC Dubai, Oct. 21-23, 2026.
  • Relfydess trial data showed rapid, sustained wrinkle improvements; pooled Phase III results showed benefits in both previously treated and toxin-naive patients.
  • Restylane studies found lasting facial improvements with good tolerability; separate Skinboosters data showed effective treatment of décolletage wrinkles.
  • Sculptra data showed lasting improvements in skin elasticity, thickness and volume, following UAE authorization expanding its use to selected body areas.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galderma Group AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261020743872) on October 21, 2026, and is solely responsible for the information contained therein.